ClinicalTrials.gg
TerminatedNCT01376700EPICUpdated May 24, 2021Results posted

Early Prophylaxis Immunologic Challenge (EPIC) Study

A Phase 3 interventional study of Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM) in Hemophilia A, sponsored by Baxalta now part of Shire. Terminated at 19 sites in 12 countries. Open to male participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2021-05-24.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Prevention

Why this study was terminated
It became unlikely to achieve the study objective of 50% reduction over published inhibitor rates. The Data Monitoring Committee supported this decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
Up to 1 Year
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
14th of 21
22 · median 50
Started
2011
with 1 other
Phase 3
4 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
8 of 21
Baxalta now part of Shire

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 14th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 3, and was the 13th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: Up to 1 Year · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of the study was to assess if a once-weekly prophylactic regimen of 25 IU/kg ADVATE started at or before 1 year of age and before the onset of a severe bleeding phenotype (ie, joint bleeding), together with the minimization of immunological danger signals, can reduce the incidence rate of inhibitor formation in PUPs with severe and moderately severe hemophilia A.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
Up to 1 Year
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with severe and moderately severe hemophilia A (FVIII ≤ 2%)
  • Participants \< 1 year of age
  • Participants must have ≤ 3 exposure days (EDs) to any FVIII concentrate or FVIII-containing product used for treatment of minor bleeds (bleeds requiring no more than 2 infusions per event), or for preventative or precautionary infusions following possible injury
  • Participants with prior circumcision are allowed to enroll only if bleeding issues related to circumcision were the cause for the original diagnosis of hemophilia A and no more than 2 EDs of FVIII treatment were required
  • Adequate venous access (without need for central venous access device (CVAD)-placement) as determined by the physician
  • Written from legally authorized representative(s)

Exclusion criteria

Exclusion Criteria:

  • Life-threatening conditions (intracranial hemorrhage, severe trauma) or requirement for surgery at the time of enrollment
  • Evidence of inhibitor ≥ 0.6 Bethesda Unit (BU) in Nijmegen-modified Bethesda Assay at study start (samples may be retested using lupus-insensitive inhibitor tests to reduce the number of false positive inhibitor test results)
  • Inherited or acquired hemostatic defect other than hemophilia A
  • Any , chronic disease other than hemophilia A
  • Known to ADVATE or any of its constituents
  • Any planned elective surgery that cannot be postponed until after the first 20 EDs
  • Participation in the Hemophilia Inhibitor Previously Untreated Patient Study
  • Application of red blood cell, , or leukocyte concentrates, or plasma
  • Administration of any medication affecting coagulation or platelet function
  • Systemic administration of any immunomodulatory drug (eg, chemotherapy, intravenous )
  • Participation in another clinical study involving an product (IP) or device within 30 days prior to study enrollment or during the course of this study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    ADVATE - Prophylactic Regimen

    Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.

    Biological: Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)

Interventions

  • BiologicalRecombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)

    Drug page: Antihemophilic factor, human recombinant

    Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.

    Also known as: ADVATE

06

What researchers measure

Primary outcomes

  1. Number of Participants With Severe and Moderately Severe Hemophilia A (FVIII ≤ 2%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE

    Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).

    Time frame: 50 exposure days to ADVATE

Secondary outcomes

  1. Number of Participants With Severe Hemophilia A (FVIII ≤ 1%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE

    Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).

    Time frame: 50 exposure days to ADVATE

  2. Number of Exposure Days of Treatment With Advate Prior to First Positive Factor VIII (FVIII) Confirmed Inhibitor Assessment

    Confirmed inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 BU/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).

    Time frame: 50 exposure days to ADVATE

  3. Number of Participants With Low-titer, High-titer, Transient, and All Factor VIII (FVIII) Inhibitors

    - High FVIII inhibitor titer (\> 5 Bethesda Unit (BU)/mL) - Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL)

    Time frame: 50 exposure days to ADVATE

  4. Number, Type, and Severity of All Bleeds Experienced When Different Prophylactic Dosing Frequencies Are Used (Once or Twice Per Week and Unknown Frequency)

    Nominal Dosing Frequency: - 1 time per week - 2 times per week - Unknown dosing frequency (UK) Bleeding Type (BT): - Skin - Muscle and Soft Tissue - Mucosal - Joint - Other - Multiple - Total Bleeding severity: - Minor - Moderate - Severe - Total

    Time frame: 50 exposure days to ADVATE

  5. Number and Type of Surgeries

    - Elective surgery is not allowed during period of first 20 exposure days (EDs) - Peripherally inserted central catheter (PICC)

    Time frame: 50 exposure days to ADVATE

  6. Correlation of Known Risk Factors to Factor VIII (FVIII) Inhibitor Formation

    Time frame: 50 exposure days to ADVATE

  7. Total Factor VIII (FVIII) Consumption by Participant

    Time frame: 50 exposure days to ADVATE

  8. FVIII-Specific Antibody Isotype for All Participants at Study Entry and Every 10 Exposure Days (EDs)

    Time frame: 50 exposure days to ADVATE

  9. Number of Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) at Least Possibly Related to ADVATE

    Possibly or probably related adverse events

    Time frame: 50 exposure days to ADVATE

07

Results

Posted Oct 9, 2014
Limitations and caveats
Early termination lead to: -No statistical tests done on risk factors \& inhibitor formation. -FVIII consumption by participant not calculated due to large variation in # of EDs. -FVIII-Specific Antibody Isotypes summary statistics not done.

Participant flow

Enrollment was conducted in Europe and North America at 19 clinical sites.

Participant flow — Overall Study
MilestoneADVATE - Prophylactic Regimen
Started19
Completed3
Not completed16
Withdrew: Sponsor terminated study early8
Withdrew: Low or high titer inhibitor8

Outcome measures

PrimaryNumber of Participants With Severe and Moderately Severe Hemophilia A (FVIII ≤ 2%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE

Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).

Time frame:
50 exposure days to ADVATE
Reported as:
Number · participants
Number of Participants With Severe and Moderately Severe Hemophilia A (FVIII ≤ 2%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE
participantsADVATE - Prophylactic Regimen
Number of Participants With Severe and Moderately Severe Hemophilia A (FVIII ≤ 2%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE8
SecondaryNumber of Participants With Severe Hemophilia A (FVIII ≤ 1%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE

Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).

Time frame:
50 exposure days to ADVATE
Reported as:
Number · participants
Number of Participants With Severe Hemophilia A (FVIII ≤ 1%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE
participantsADVATE - Prophylactic Regimen
Number of Participants With Severe Hemophilia A (FVIII ≤ 1%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE8
SecondaryNumber of Exposure Days of Treatment With Advate Prior to First Positive Factor VIII (FVIII) Confirmed Inhibitor Assessment

Confirmed inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 BU/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (\> 5 BU/mL) or - ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL).

Time frame:
50 exposure days to ADVATE
Reported as:
Median · days
Number of Exposure Days of Treatment With Advate Prior to First Positive Factor VIII (FVIII) Confirmed Inhibitor Assessment
daysADVATE - Prophylactic Regimen
Number of Exposure Days of Treatment With Advate Prior to First Positive Factor VIII (FVIII) Confirmed Inhibitor Assessment14.5 (7.0 to 21.0)
SecondaryNumber of Participants With Low-titer, High-titer, Transient, and All Factor VIII (FVIII) Inhibitors

- High FVIII inhibitor titer (\> 5 Bethesda Unit (BU)/mL) - Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL)

Time frame:
50 exposure days to ADVATE
Reported as:
Number · participants
Number of Participants With Low-titer, High-titer, Transient, and All Factor VIII (FVIII) Inhibitors
participantsADVATE - Prophylactic Regimen
Low FVIII inhibitor titer5
High FVIII inhibitor titer3
All FVIII inhibitors8
SecondaryNumber, Type, and Severity of All Bleeds Experienced When Different Prophylactic Dosing Frequencies Are Used (Once or Twice Per Week and Unknown Frequency)

Nominal Dosing Frequency: - 1 time per week - 2 times per week - Unknown dosing frequency (UK) Bleeding Type (BT): - Skin - Muscle and Soft Tissue - Mucosal - Joint - Other - Multiple - Total Bleeding severity: - Minor - Moderate - Severe - Total

Time frame:
50 exposure days to ADVATE
Reported as:
Number · Bleeds
Number, Type, and Severity of All Bleeds Experienced When Different Prophylactic Dosing Frequencies Are Used (Once or Twice Per Week and Unknown Frequency)
BleedsADVATE - Prophylactic Regimen
Dose: 1/week; Skin; Minor Bleed130
Dose: 1/week; Skin; Moderate Bleed2
Dose: 1/week; Skin; Severe Bleed0
Dose: 1/week; Skin; Total Bleeds132
Dose: 1/week; Muscle & Soft Tissue; Minor Bleed8
Dose: 1/week; Muscle & Soft Tissue; Moderate Bleed10
Dose: 1/week; Muscle & Soft Tissue; Severe Bleed0
Dose: 1/week; Muscle & Soft Tissue; Total Bleeds18
Dose: 1/week; Mucosal; Minor Bleed9
Dose: 1/week; Mucosal; Moderate Bleed3
Dose: 1/week; Mucosal; Severe Bleed0
Dose: 1/week; Mucosal; Total Bleeds12
Dose: 1/week; Joint; Minor Bleed0
Dose: 1/week; Joint; Moderate Bleed0
Dose: 1/week; Joint; Severe Bleed0
Dose: 1/week; Joint; Total Bleeds0
Dose: 1/week; Other BT; Minor Bleed3
Dose: 1/week; Other BT; Moderate Bleed3
Dose: 1/week; Other BT; Severe Bleed1
Dose: 1/week; Other BT; Total Bleeds7
Dose: 1/week; Multiple BT; Minor Bleed2
Dose: 1/week; Multiple BT; Moderate Bleed1
Dose: 1/week; Multiple BT; Severe Bleed0
Dose: 1/week; Multiple BT; Total Bleeds3
Dose: 1/week; Total BT; Minor Bleed152
Dose: 1/week; Total BT; Moderate Bleed19
Dose: 1/week; Total BT; Severe Bleed1
Dose: 1/week; Total BT; Total Bleeds172
Dose: 2/week; Skin; Minor Bleed9
Dose: 2/week; Skin; Moderate Bleed0
Dose: 2/week; Skin; Severe Bleed0
Dose: 2/week; Skin; Total Bleeds9
Dose: 2/week; Muscle & Soft Tissue; Minor Bleed0
Dose: 2/week; Muscle & Soft Tissue; Moderate Bleed1
Dose: 2/week; Muscle & Soft Tissue; Severe Bleed0
Dose: 2/week; Muscle & Soft Tissue; Total Bleeds1
Dose: 2/week; Mucosal; Minor Bleed3
Dose: 2/week; Mucosal; Moderate Bleed1
Dose: 2/week; Mucosal; Severe Bleed0
Dose: 2/week; Mucosal; Total Bleeds4
Dose: 2/week; Joint; Minor Bleed0
Dose: 2/week; Joint; Moderate Bleed0
Dose: 2/week; Joint; Severe Bleed0
Dose: 2/week; Joint; Total Bleeds0
Dose: 2/week; Other BT; Minor Bleed0
Dose: 2/week; Other BT; Moderate Bleed0
Dose: 2/week; Other BT; Severe Bleed0
Dose: 2/week; Other BT; Total Bleeds0
Dose: 2/week; Multiple BT; Minor Bleed0
Dose: 2/week; Multiple BT; Moderate Bleed0
Dose: 2/week; Multiple BT; Severe Bleed0
Dose: 2/week; Multiple BT; Total Bleeds0
Dose: 2/week; Total BT; Minor Bleed12
Dose: 2/week; Total BT; Moderate Bleed2
Dose: 2/week; Total BT; Severe Bleed0
Dose: 2/week; Total BT; Total Bleeds14
Dose: UK/week; Skin; Minor Bleed4
Dose: UK/week; Skin; Moderate Bleed1
Dose: UK/week; Skin; Severe Bleed0
Dose: UK/week; Skin; Total Bleeds5
Dose: UK/week; Muscle & Soft Tissue; Minor Bleed0
Dose: UK/week; Muscle & Soft Tissue;Moderate Bleed1
Dose: UK/week; Muscle & Soft Tissue; Severe Bleed0
Dose: UK/week; Muscle & Soft Tissue; Total Bleeds1
Dose: UK/week; Mucosal; Minor Bleed0
Dose: UK/week; Mucosal; Moderate Bleed0
Dose: UK/week; Mucosal; Severe Bleed0
Dose: UK/week; Mucosal; Total Bleeds0
Dose: UK/week; Joint; Minor Bleed0
Dose: UK/week; Joint; Moderate Bleed1
Dose: UK/week; Joint; Severe Bleed0
Dose: UK/week; Joint; Total Bleeds1
Dose: UK/week; Other BT; Minor Bleed0
Dose: UK/week; Other BT; Moderate Bleed0
Dose: UK/week; Other BT; Severe Bleed0
Dose: UK/week; Other BT; Total Bleeds0
Dose: UK/week; Multiple BT; Minor Bleed0
Dose: UK/week; Multiple BT; Moderate Bleed0
Dose: UK /week; Multiple BT; Severe Bleed0
Dose: UK /week; Multiple BT; Total Bleeds0
Dose: UK /week; Total BT; Minor Bleed4
Dose: UK /week; Total BT; Moderate Bleed3
Dose: UK /week; Total BT; Severe Bleed0
Dose: UK /week; Total BT; Total Bleeds7
SecondaryNumber and Type of Surgeries

- Elective surgery is not allowed during period of first 20 exposure days (EDs) - Peripherally inserted central catheter (PICC)

Time frame:
50 exposure days to ADVATE
Reported as:
Number · surgeries
Number and Type of Surgeries
surgeriesADVATE - Prophylactic Regimen
Surgery: Cimino Shunt1
Surgery: PICC Line Insertion in right arm1
SecondaryCorrelation of Known Risk Factors to Factor VIII (FVIII) Inhibitor Formation
Time frame:
50 exposure days to ADVATE

No measurements were reported for this outcome.

SecondaryTotal Factor VIII (FVIII) Consumption by Participant
Time frame:
50 exposure days to ADVATE

No measurements were reported for this outcome.

SecondaryFVIII-Specific Antibody Isotype for All Participants at Study Entry and Every 10 Exposure Days (EDs)
Time frame:
50 exposure days to ADVATE

No measurements were reported for this outcome.

SecondaryNumber of Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) at Least Possibly Related to ADVATE

Possibly or probably related adverse events

Time frame:
50 exposure days to ADVATE
Reported as:
Number · adverse events
Number of Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) at Least Possibly Related to ADVATE
adverse eventsADVATE - Prophylactic Regimen
SAEs9
non-SAEs1
Post-hocNumber of Participants With Factor VIII (FVIII) Inhibitors by Inhibitor Type (Only 'True' Inhibitors)

'True' positive inhibitor (PI) defined as any FVIII inhibitor assay result ≥0.6 Bethesda Units (BU)/mL confirmed by central lab on 2 consecutive samples, ie ≥2 PI results (including first PI test, in accordance with study protocol) assessed as either: i. High FVIII inhibitor titer (\> 5 BU/mL) ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL). In addition, to be classified as 'true' positive low FVIII inhibitors titer (≥0.6 - ≤5.0 BU/mL), one of following criteria must be met: - a) Lower or absent therapeutic response at infusion of standard replacement doses ("clinically relevant") as deemed by the clinician in charge. - b) Any lab result of binding FVIII antibodies (IgM, IgA, IgG, IgG1, IgG2, IgG3, or IgG4) must be positive. Classification based on first positive FVIII inhibitor assessment. Inhibitor test result is: - \> 5 BU/mL, then categorized as a high-titer inhibitor - ≥0.6 BU/mL but ≤5 BU/mL, then categorized as a low-titer.

Time frame:
50 exposure days to ADVATE
Reported as:
Number · participants
Number of Participants With Factor VIII (FVIII) Inhibitors by Inhibitor Type (Only 'True' Inhibitors)
participantsADVATE - Prophylactic Regimen
Inhibitor Type: Low-Titer3 (3.4 to 39.6)
Inhibitor Type: High-Titer3 (3.4 to 39.6)
Inhibitor Type: All Inhibitors6 (12.6 to 56.6)
Post-hocNumber of Inhibitors in Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) - (Only 'True' Inhibitors)

PUPs = no previous FVIII exposure; MTPs ≤4 previous FVIII exposures 'True' positive inhibitor (PI) = any FVIII inhibitor assay result ≥0.6 Bethesda Units (BU)/mL confirmed by central lab on 2 consecutive samples, ie ≥2 PI results (including first PI test, per study protocol) assessed as either: i. High FVIII inhibitor titer (\>5 BU/mL) ii. Low FVIII inhibitor titer (≥0.6 - ≤5.0 BU/mL). In addition, to be classified as 'true' positive low FVIII inhibitors titer (≥0.6 - ≤5.0 BU/mL), one of following criteria must be met: - a) Lower or absent therapeutic response at infusion of standard replacement doses ("clinically relevant") as deemed by clinician in charge. - b) Any lab result of binding FVIII antibodies (IgM, IgA, IgG, IgG1, IgG2, IgG3, or IgG4) must be positive. Classification based on first positive FVIII inhibitor assessment. Inhibitor test result is: - \> 5 BU/mL, categorized as high-titer inhibitor - ≥0.6 BU/mL but ≤5 BU/mL, categorized as low-titer

Time frame:
50 exposure days to ADVATE
Reported as:
Number · inhibitors
Number of Inhibitors in Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) - (Only 'True' Inhibitors)
inhibitorsPUPsMTPs
Number of Inhibitors in Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) - (Only 'True' Inhibitors)33

Adverse events

Collected over 1 year and 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADVATE - Prophylactic Regimen—11/19 (57.9%)19/19 (100%)
Most frequent serious events
Most frequent serious events
EventADVATE - Prophylactic Regimen
FACTOR VIII INHIBITIONBlood and lymphatic system disorders8/19
HAEMORRHAGEVascular disorders2/19
HEAD INJURYInjury, poisoning and procedural complications1/19
TRAUMATIC HAEMATOMAInjury, poisoning and procedural complications1/19
SOFT TISSUE HAEMORRHAGEMusculoskeletal and connective tissue disorders1/19
ARTERIOVENOUS FISTULA OPERATIONSurgical and medical procedures1/19
Most frequent other events
Showing 10 of 46
Most frequent other events
EventADVATE - Prophylactic Regimen
PYREXIAGeneral disorders10/19
RHINITISInfections and infestations8/19
NASOPHARYNGITISInfections and infestations6/19
COUGHRespiratory, thoracic and mediastinal disorders6/19
VOMITINGGastrointestinal disorders5/19
TEETHINGGastrointestinal disorders4/19
DIARRHOEAGastrointestinal disorders3/19
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/19
RASHSkin and subcutaneous tissue disorders3/19
EAR INFECTIONInfections and infestations2/19

Baseline characteristics

Age, Continuous
Age, Continuous(weeks)ADVATE - Prophylactic Regimen
Mean43.3 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)ADVATE - Prophylactic Regimen
Female0
Male19
Region of Enrollment
Region of Enrollment(Participants)ADVATE - Prophylactic Regimen
Serbia1
United States2
Czech Republic2
Canada1
Spain1
Poland4
Austria1
Russian Federation3
Bulgaria1
Netherlands1
Germany2
08

Study locations

19 sites
  • Indianapolis, Indiana, United States
  • New Brunswick, New Jersey, United States
  • Vienna, Austria
  • Sofia, Bulgaria
  • Kingston, Ontario, Canada
  • Brno, Czechia
  • Bonn, Germany
  • Bremen, Germany
  • Giessen, Germany
  • Munich, Germany
  • Vilnius, Lithuania
  • Nijmegen, Netherlands
  • Lublin, Poland
  • Olsztyn, Poland
  • Chelyabinsk, Russian Federation
  • Krasnodar, Russian Federation
  • St. Petersburg, Russian Federation
  • Belgrade, Serbia
  • A Coruña, Spain
09

References and documents

Publications

  • Auerswald G, Kurnik K, Aledort LM, Chehadeh H, Loew-Baselli A, Steinitz K, Reininger AJ; EPIC clinical study group. The EPIC study: a lesson to learn. Haemophilia. 2015 Sep;21(5):622-8. doi: 10.1111/hae.12666. Epub 2015 Apr 23. PubMed 25912619 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2011 to primary completion in Nov 2012, 14 months.

Results were first posted in Oct 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2011
First posted
Jun 20, 2011
StartActual
Aug 26, 2011
Primary completionActual
Nov 16, 2012
CompletionActual
Nov 16, 2012
Results first posted
Oct 9, 2014
Last update
May 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01376700
Collaborators
Baxter Innovations GmbH
Responsible party
Sponsor
First posted
Jun 20, 2011
Start date
Aug 26, 2011
Primary completion
Nov 16, 2012
Completion
Nov 16, 2012
Results posted
Oct 9, 2014
Last update
May 24, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antihemophilic factor, human recombinant

Start the discussion